News | August 12, 2021
Hester Biosciences posts PAT of Rs 11.01 cr in Q1FY22
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
India business is growing as per projections; whereas US business will bounce back soon.
Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated
